Table 2.
Clinical features of functional pancreatic neuroendocrine tumors
| Tumor | Percentage | Secreted hormone | Malignant | Clinical features | Biochemical evaluation |
| Insulinoma | 40%-60% | Insulin | < 10% | Hypoglycemia | Insulin, pro-insulin, C-peptide, 72 h fasting insulin/glucose ratio |
| Gastrinoma | 20%-50% | Gastrin | 60%-90% | PUD, GERD, diarrhea | Fasting gastrin (off PPI), secretin stimulation test |
| Glucagonoma | Rare | Glucagon | 50%-80% | Necrolytic migratory erythema, diabetes, venous thrombosis, depression | Glucagon |
| Somatostatinoma | Rare | Somatostatin | > 70% | Diabetes, hypochlorhydria, cholelithiasis, diarrhea | Somatostatin (not widely available) |
| VIPoma | Rare | Vasoactive Intestinal Peptide | 40%-70% | Watery diarrhea, hypokalemia, achlorhydria | VIP |
PUD: Peptic ulcer disease; GERD: Gastroesophageal reflux disease; PPI: Proton pump inhibitor.